An observational study in Heart Failure, sponsored by Chongqing Medical University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-16.
Sponsored by Chongqing Medical University · Observational
This study is a multicenter retrospective research aimed at developing a heart failure prognosis warning system based on multimodal clinical data to improve the diagnosis and treatment of heart failure.
This study aims to address the following main questions:
5,701 studies on the registry are indexed under Heart Failure; 1,220 are open to participants now.
This study's planned enrollment of 100,000 is above the median of 200 across 1,679 observational studies indexed under Heart Failure.
Browse Heart Failure studies →Chongqing Medical University is the lead sponsor of 75 studies on the registry; 17 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population for this research consists of adult patients, aged 18 and above, with a discharge diagnosis of heart failure between January 2011 and December 2024, as per the guidelines for the diagnosis and treatment of heart failure . The patients' electronic medical records, which include demographic information, comorbidities, treatment plans, and various clinical indicators, are sourced , ensuring a comprehensive and in-depth analysis of the heart failure patient cohort.
Age Requirement: We plan to include adult patients aged 18 and above to ensure the study covers a broad spectrum of the adult heart failure patient population.
Diagnostic Criteria: Patients should have a discharge diagnosis of heart failure according to the guidelines for heart failure diagnosis and treatment.
Time Frame: The discharge time of patients should be between January 2011 and December 2024 to collect and analyze data from the past several years.
Data Integrity: There is a preference for including medical records with high data integrity, but the specific criteria may be adjusted according to the actual situation of the dataset.
Exclusion Criteria:
Data Missing: Patients with more than 30% missing data in their medical records may be considered for exclusion to ensure the accuracy and reliability of the analysis.
Diagnostic Inconsistency: Patients with unclear diagnoses or potential for confusion with other diseases may be excluded to ensure the specificity of the study.
Non-standard Treatment: Patients who have not received treatment according to the established treatment protocol may be excluded to reduce the impact of treatment variability on the study results.
In-hospital mortality or other adverse outcomes, including readmission, in-hospital infection, respiratory failure, liver failure, and renal failure.
The study focuses on evaluating the risk factors and predictors of in-hospital mortality and various adverse outcomes in heart failure patients, encompassing events such as readmission due to exacerbation of the condition, infections acquired during hospital stay, critical impairments in respiratory, liver, and kidney functions that may complicate the clinical course and impact patient prognosis.
Time frame: Evaluations will be conducted within 30, 60, or 90 days post-admission for heart failure patients to assess the impact of the condition and the effectiveness of treatment.
No study locations are listed for this record.
Plan to share: No — The data analyzed in this study are subject to the following licenses/restrictions: due to ethics committee regulations, the access to the dataset supporting the findings of this study is limited and not public. Requests to access these datasets should be directed to XZ Liu(xiaozhuliu2021@163.com).
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chongqing Medical University